Coherus Oncology Inc. has announced new multiomic tumor and blood-based biomarker data from the dose expansion arm of its ongoing Phase 1b clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The results were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer $(SITC)$ held November 5-9, 2025, in National Harbor, Maryland. The data demonstrated that CHS-114 selectively depleted CCR8+ regulatory T cells (Tregs) in both tumor tissue and blood samples, sparing non-CCR8+ Tregs, CD4+ T cells, and CD8+ T cells. Treatment with CHS-114 resulted in more than a 50% increase in intratumoral CD8+ T cells and significant increases in markers of immune activation. The combination of CHS-114 and toripalimab also showed robust and sustained CD8+ T cell proliferation and increased Th1 inflammatory cytokine levels. The ongoing study is assessing dose optimization and safety to inform further clinical development.